Full Year 2025 Guidance
BeiGene's financial guidance is summarized below:
| FY 20251 | ||||
| Total Revenue | $4.9 billion to $5.3 billion | |||
| GAAP Operating Expenses (R&D and SG&A) | $4.1 billion to $4.4 billion | |||
| Additional: | GAAP Gross Margin Percentage in mid-80% range | |||
| Positive Full Year GAAP Operating Income | ||||
| Generation of Positive Cash Flow from Operations | ||||
BeiGene's total revenue guidance for full year 2025 of $4.9 billion to $5.3 billion includes expectations for strong revenue growth driven by BRUKINSA's U.S. leadership position and continued global expansion in both Europe and other important rest of world markets. Gross margin percentage is expected to be in the mid-80% range due to mix and production efficiencies as compared to 2024.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。